

KIAA1383 siRNA (h): sc-88485

BACKGROUND

KIAA1383 is a 905 amino acid protein that is serine rich and post-translationally modified at serine 682. The gene encoding KIAA1383 maps to human chromosome 1q42.2, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Eudy, J.D., Weston, M.D., Yao, S., Hoover, D.M., Rehm, H.L., Ma-Edmonds, M., Yan, D., Ahmad, I., Cheng, J.J., Ayuso, C., Cremers, C., Davenport, S., Moller, C., et al. 1998. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. *Science* 280: 1753-1757.
2. Nagase, T., Kikuno, R., Ishikawa, K.I., Hirose, M. and Ohara, O. 2000. Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins *in vitro*. *DNA Res.* 7: 65-73.
3. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
4. Pasilova, M., Russell, A.M., Wanner, A., Wolf, A., Dobbie, Z., Müller, H.J. and Heinemann, K. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
5. Olsen, J.V., Blagoev, B., Gnani, F., Macek, B., Kumar, C., Mortensen, P. and Mann, M. 2006. Global, *in vivo*, and site-specific phosphorylation dynamics in signaling networks. *Cell* 127: 635-648.
6. Betarbet, R., Anderson, L.R., Gearing, M., Hodges, T.R., Fritz, J.J., Lah, J.J. and Levey, A.I. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
7. Holliday, E.G., Nyholt, D.R., Tirupati, S., John, S., Ramachandran, P., Ramamurti, M., Ramadoss, A.J., Jeyagurunathan, A., Kottiswaran, S., Smith, H.J., Filippich, C., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
8. Balcáková, J., Urbánková, H., Scudla, V., Holzerová, M., Bacovský, J., Indrák, K. and Jarosová, M. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. *Cancer Genet. Cytogenet.* 192: 68-72.
9. Yokoi, T., Koide, R., Matsuoka, K., Nakagawa, A. and Azuma, N. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes Arch. Clin. Exp. Ophthalmol.* 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: MAP10 (human) mapping to 1q42.2.

PRODUCT

KIAA1383 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see KIAA1383 shRNA Plasmid (h): sc-88485-SH and KIAA1383 shRNA (h) Lentiviral Particles: sc-88485-V as alternate gene silencing products.

For independent verification of KIAA1383 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-88485A, sc-88485B and sc-88485C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

KIAA1383 siRNA (h) is recommended for the inhibition of KIAA1383 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor KIAA1383 gene expression knockdown using RT-PCR Primer: KIAA1383 (h)-PR: sc-88485-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.